ESCAPE Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely targeted therapeutics for genetically defined neurodegenerative diseases. ESB1609 is in a Phase 1 multiple ascending dose study in healthy volunteers. ESCAPE has advanced a mutant-selective LRRK2 G2019S kinase inhibitor for Parkinson's Disease (PD) patients to IND-enabling studies. A pharmacologic structure corrector of Alzheimer's patients carrying the ApoE4 risk allele is in Discovery.
View Top Employees from E-Scape Bio Inc| Website | http://escapebio.com |
| Revenue | $15 million |
| Funding | $182 million |
| Employees | 1 (1 on RocketReach) |
| Address | 4000 Shoreline Ct, Ste 400, South San Francisco, California 94080, US |
| Phone | (650) 431-0100 |
| Category | Pharmaceuticals, Healthcare, Biotechnology, Drug Manufacturing & Research |
| Competitors | Acadia Pharmaceuticals Inc., Asceneuron SA, Cognition Therapeutics, Inc., Exosome Diagnostics, Miroculus |
| SIC | 87, 873 |
| NAICS | 54, 541713, 5417, 541, 54171 |
Looking for a particular E-Scape Bio Inc employee's phone or email?
E-Scape Bio Inc Questions
The E-Scape Bio Inc annual revenue was $15 million in 2023.
1 people are employed at E-Scape Bio Inc.
E-Scape Bio Inc is based in South San Francisco, California.
The NAICS codes for E-Scape Bio Inc are [54, 541713, 5417, 541, 54171].
The SIC codes for E-Scape Bio Inc are [87, 873].
Top E-Scape Bio Inc Employees
